ORIC Pharmaceuticals Reports Inducement Grants

Grants made under Nasdaq Listing Rule 5635(c)(4) to new non-executive employee

Apr. 3, 2026 at 8:45pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of stock certificates, a pen, and a calculator arranged elegantly on a clean white background, conceptually representing the financial tools and strategies used by biotech companies to incentivize and retain key employees.Equity incentives help ORIC Pharmaceuticals attract top talent to drive innovation in cancer treatment.San Diego Today

ORIC Pharmaceuticals, a clinical-stage oncology company, announced that on April 1, 2026, it granted a total of 80,000 non-qualified stock options and 15,000 restricted stock units to one new non-executive employee who began their employment with ORIC in March 2026. These inducement grants were made pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.

Why it matters

The inducement grants are a common practice for public companies to attract and retain top talent, especially in the competitive biotech industry. These grants provide the new employee with an equity stake in the company, aligning their interests with those of ORIC's shareholders.

The details

The stock options have an exercise price equal to the closing price of ORIC's common stock on the grant date. Twenty-five percent of the shares subject to the stock options will vest on the one-year anniversary of the grant date, with the remaining shares vesting monthly over the following three years. One-third of the restricted stock units will vest on each of the first three anniversaries of the grant date.

  • The grants were made on April 1, 2026.
  • The new employee began their employment with ORIC in March 2026.

The players

ORIC Pharmaceuticals, Inc.

A clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance.

ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan

The plan under which the inducement grants were made.

Got photos? Submit your photos here. ›

The takeaway

The inducement grants to a new non-executive employee demonstrate ORIC's commitment to attracting and retaining top talent in the competitive biotech industry, which is crucial for the company's continued success in developing innovative cancer treatments.